Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Phase 2 Completed
46 enrolled 7 charts
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
Phase 1 Completed
153 enrolled
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Phase 2 Completed
12 enrolled 21 charts
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
68 enrolled 7 charts
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
172 enrolled 13 charts
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
64 enrolled 7 charts
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
Phase 2 Completed
60 enrolled 7 charts
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
Phase 2 Completed
2 enrolled 5 charts
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
Phase 2 Completed
73 enrolled 9 charts
Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
12 enrolled 7 charts
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
Phase 2 Completed
15 enrolled
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
Phase 1 Completed
104 enrolled
S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
60 enrolled
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
13 enrolled 5 charts
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
18 enrolled